142 related articles for article (PubMed ID: 23360698)
21. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
22. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
[TBL] [Abstract][Full Text] [Related]
23. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
24. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
25. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
26. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
27. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
28. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
29. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer.
Maxwell C
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():35-40. PubMed ID: 23360701
[TBL] [Abstract][Full Text] [Related]
30. [Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Nortier JW
Ned Tijdschr Geneeskd; 2004 Jul; 148(31):1524-8. PubMed ID: 15366720
[TBL] [Abstract][Full Text] [Related]
31. Novel taxanes.
Muggia F; Kudlowitz D
Anticancer Drugs; 2014 May; 25(5):593-8. PubMed ID: 24374330
[TBL] [Abstract][Full Text] [Related]
32. Weekly taxanes in metastatic breast cancer (review).
Zimatore M; Danova M; Vassallo E; Porta C; Macaluso MC; Schittone L; Riccardi A; Palmeri S
Oncol Rep; 2002; 9(5):1047-52. PubMed ID: 12168071
[TBL] [Abstract][Full Text] [Related]
33. Taxanes in adjuvant breast cancer setting: which standard in Europe?
Campone M; Fumoleau P; Bourbouloux E; Kerbrat P; Roché H
Crit Rev Oncol Hematol; 2005 Sep; 55(3):167-75. PubMed ID: 16039867
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Yonemori K; Katsumata N; Uno H; Matsumoto K; Kouno T; Tokunaga S; Yamanaka Y; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2005 Feb; 89(3):237-41. PubMed ID: 15754121
[TBL] [Abstract][Full Text] [Related]
35. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
37. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
38. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Dang CT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
[TBL] [Abstract][Full Text] [Related]
39. Current status of taxanes as adjuvant therapy for early-stage breast cancer.
Wolff AC
Int J Fertil Womens Med; 2005; 50(5 Pt 1):227-9. PubMed ID: 16468473
[TBL] [Abstract][Full Text] [Related]
40. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.
Rivera E; Cianfrocca M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):659-70. PubMed ID: 25596818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]